New Delhi: Serum Institute of India, the
country`s largest vaccine maker, today announced the launch of
its indigenously developed intra-nasal vaccine, Nasovac, for
preventing H1N1 infections.
The single dose vaccine, fitted at the top of a syringe,
is just to be sniffed once in each nostril, making it a
painless prevention mode, the company said in a statement.
The vaccine is approved by the Drug Controller General of
India (DCGI) for usage by any individual above three years of
age, except pregnant women, and is economically priced so that
it is affordable for the masses.
"Last year, we saw the panic due to fears about the H1N1
pandemic. I am happy that Serum has done its part in making
the country self-reliant in creating vaccines for preventing
pandemic influenza in the future," Serum Institute of India
Chairman Cyrus Poonawalla said.
With the outbreak of H1N1 infections in 2009, the Serum
Institute, in consultation with the World Health Organisation
(WHO) and the Ministry of Health, had started work on the H1N1
The company is also working on an influenza vaccine under
Serum Institute of India is the world`s largest DTP
(Triple) and measles vaccine manufacturer. The company`s
products are exported to over 130 countries worldwide.